

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

AN3-CA

RRID:CVCL_0028

Type: Cell Line

Proper Citation

RRID:CVCL_0028

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0028

Proper Citation: RRID:CVCL_0028

Description: Cell line AN3-CA is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Acanthosis nigricans

Defining Citation: [PMID:327080](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:11668190](#), [PMID:14207855](#), [PMID:16957166](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20218740](#), [PMID:20944090](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: MD Anderson Cell Lines Project., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ERK genetic alteration cell panel (ATCC TCP-1033)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AN3-CA

Synonyms: AN3_CA, AN3 CA, AN3 Ca, AN3CA, AN-3, AN3, Acanthosis Nigricans 3rd attempt-CArcinoma

Cross References: BTO:BTO_0001771, CLO:CLO_0001722, CLO:CLO_0037160, EFO:EFO_0002110, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783,

ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-111, BCRJ:0363, BioSample:SAMN03471092, BioSample:SAMN03473131, BioSample:SAMN03473336, BioSample:SAMN10988375, cancercellines:CVCL_0028, CCRID:4201HUM-CCTCC00127, CCTCC:GDC0127, Cell_Model_Passport:SIDM00901, ChEMBL-Cells:ChEMBL3308708, ChEMBL-Targets:ChEMBL1075392, CLS:300119, Cosmic:687550, Cosmic:699283, Cosmic:713473, Cosmic:713495, Cosmic:809134, Cosmic:846176, Cosmic:871551, Cosmic:889116, Cosmic:910781, Cosmic:980634, Cosmic:1007162, Cosmic:1057760, Cosmic:1066221, Cosmic:1070810, Cosmic:1102376, Cosmic:1105620, Cosmic:1177683, Cosmic:1223484, Cosmic:1434192, Cosmic:1576450, Cosmic:1622894, Cosmic:1696752, Cosmic:2030460, Cosmic:2646618, Cosmic-CLP:910781, DepMap:ACH-000940, DSMZ:ACC-267, DSMZCellDive:ACC-267, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910781, GEO:GSM374970, GEO:GSM375429, GEO:GSM827494, GEO:GSM886869, GEO:GSM887934, GEO:GSM1669600, GEO:GSM3161710, GEO:GSM3161711, GEO:GSM7701431, GEO:GSM7701432, IARC_TP53:21175, IGRhCellID:AN3CA, IZSLER:BS TCL 200, LiGeA:CCLE_574, LINCS_LDP:LCL-1499, PharmacDB:AN3CA_63_2019, PRIDE:PXD030304, Progenetix:CVCL_0028, PubChem_Cell_line:CVCL_0028, TOKU-E:543, Wikidata:Q54749896

ID: CVCL_0028

Record Creation Time: 20220427T215219+0000

Record Last Update: 20260904T021347+0000

Ratings and Alerts

No rating or validation information has been found for AN3-CA.

No alerts have been found for AN3-CA.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Peng J, et al. (2026) CBLC-mediated ubiquitination stabilizes METTL1, enhances N7-methylguanosine modification of ESRRA, and promotes the progression of endometrial cancer. International journal of biological macromolecules, 369, 152809.

Carballo EV, et al. (2025) The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer. Clinical cancer

research : an official journal of the American Association for Cancer Research, 31(24), 5294.

Yang Z, et al. (2025) Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. *Cancer research communications*, 5(4), 719.

Satpathy S, et al. (2025) Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. *Cancer cell*, 43(9), 1731.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Dong X, et al. (2024) ST6GALNAC1-mediated sialylation in uterine endometrial epithelium facilitates the epithelium-embryo attachment. *Journal of advanced research*.

Gong X, et al. (2024) Pyroptosis-associated genes and tumor immune response in endometrial cancer. *Discover oncology*, 15(1), 433.

Lv M, et al. (2024) TSLP enhances progesterin response in endometrial cancer via androgen receptor signal pathway. *British journal of cancer*, 130(4), 585.

Yang X, et al. (2023) PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. *Molecular oncology*.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.

Patil A, et al. (2023) A disordered region controls cBAF activity via condensation and partner recruitment. *Cell*, 186(22), 4936.

O'Connor CM, et al. (2022) Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. *Cancer research*, 82(4), 721.

Wu Y, et al. (2021) MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. *Gynecologic oncology*, 163(1), 181.

Peck B, et al. (2021) 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. *Cancer research*, 81(4), 847.

Ohki Y, et al. (2019) Perturbation-Based Proteomic Correlation Profiling as a Target Deconvolution Methodology. *Cell chemical biology*, 26(1), 137.

Yasuhara T, et al. (2018) Human Rad52 Promotes XPG-Mediated R-loop Processing to Initiate Transcription-Associated Homologous Recombination Repair. *Cell*, 175(2), 558.